Stock Split History
ETFs Holding RARE »    RARE Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co.'s product categories are: biologics, which include Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and Mepsevii® (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII; small molecules, which includes UX007 for the treatment of long-chain fatty acid oxidation disorders; and gene therapy, which includes DTX301 for the treatment of patients with ornithine transcarbamylase deficiency and DTX401 for the treatment of patients with glycogen storage disease type Ia. According to our Ultragenyx Pharmaceutical stock split history records, Ultragenyx Pharmaceutical has had 2 splits.
Ultragenyx Pharmaceutical stock split history picture
Ultragenyx Pharmaceutical (RARE) has 2 splits in our Ultragenyx Pharmaceutical stock split history database. The first split for RARE took place on September 06, 2000. This was a 3 for 2 split, meaning for each 2 shares of RARE owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. RARE's second split took place on September 03, 2003. This was a 3 for 2 split, meaning for each 2 shares of RARE owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.

When a company such as Ultragenyx Pharmaceutical splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the Ultragenyx Pharmaceutical stock split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ultragenyx Pharmaceutical shares, starting with a $10,000 purchase of RARE, presented on a split-history-adjusted basis factoring in the complete Ultragenyx Pharmaceutical stock split history. Ultragenyx Pharmaceutical split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 01/31/2014
End date: 05/17/2021
Start price/share: $42.25
End price/share: $110.29
Dividends collected/share: $0.00
Total return: 161.04%
Average Annual Total Return: 14.06%
Starting investment: $10,000.00
Ending investment: $26,102.51
Years: 7.29
Date Ratio
09/06/20003 for 2
09/03/20033 for 2
RARE is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

RCKT Split History
RCPI Split History
RDNT Split History
RDY Split History
REPH Split History
RGLS Split History
RHE Split History
RMD Split History
RNN Split History
RNVA Split History

Also explore: RARE shares outstanding history

LM Funding America, Inc. (LMFA)
Foxby Corp. (XFXBX)
InspireMD, Inc. (NSPR)
Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Insider Buying

Ultragenyx Pharmaceutical Stock Split History | www.StockSplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.StockSplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.